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ABSTRACT
Campylobacter is the most common cause of bacterial gastroenteritis worldwide. This study describes
regional and seasonal differences among culture-proven Campylobacter infections in The Netherlands in
2000–2004. Data were used from two ongoing projects in The Netherlands, covering 3 million and
8 million inhabitants, respectively, for surveillance of infectious diseases. The incidence of Campylobacter
infection was highest in the south of The Netherlands (55.7 ⁄ 100 000 vs. an average of 39.1 ⁄ 100 000 in
other regions). The incidence in urbanised areas was 41.9 ⁄ 100 000 vs. 32.4 ⁄ 100 000 in rural areas. High
stable rates of resistance to ﬂuoroquinolones (35%) were observed. Resistance to erythromycin increased
from 1.9% (in 2001) to 2.7% (in 2004). The highest rates of resistance to erythromycin were found in the
south. Resistance rates increased with increasing urbanisation, most obviously for ﬂuoroquinolones
(35.9% urban vs. 27.10% rural). An inverse relationship was observed between the incidence of infection
(high in summer, low in winter) and resistance to both ﬂuoroquinolones and macrolides. Resistance to
ﬂuoroquinolones was higher in travel-related infections (54%) than in endemic infections (33%).
Differences in regional incidence and resistance rates of Campylobacter infections were found. Foreign
travel appeared to be associated with higher resistance rates. Given the high ﬂuoroquinolone resistance
rate, empirical treatment of severe, microbiologically conﬁrmed, Campylobacter infection with a
ﬂuoroquinolone should be discouraged, pending susceptibility testing.
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INTRODUCTION
Infections with Campylobacter spp. are the most
frequent cause of bacterial gastroenteritis in
industrialised and developing countries world-
wide [1–5]. The number of infections has risen
several-fold during the past two decades. A
consensus seems to have emerged that this rise
is caused largely by increased consumption of
poultry meat [6,7]. Most often, infections with
Campylobacter spp. cause a self-limiting diarrhoeal
illness and need not be treated with antimicrobial
agents, although Campylobacter infections may be
followed by severe complications [8]. Antimicro-
bial therapy is necessary for patients with severe
and prolonged enteritis (particularly neonates
and elderly individuals), suspected septicaemia,
other invasive extra-intestinal manifestations, and
patients with a severe underlying illness (e.g.,
hypo- or agammaglobulinaemia or human immu-
nodeﬁciency virus infection). Drugs of choice
include ciproﬂoxacin [9] for early empirical treat-
ment of adults, especially for travel-related dis-
ease, and erythromycin for treatment following
microbiological conﬁrmation [1,10].
During the 1990s, resistance to ﬂuoroquinolo-
nes among Campylobacter spp. increased signiﬁ-
cantly in The Netherlands and other European
countries [11,12]. The increase in quinolone
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resistance has been associated with the introduc-
tion of ﬂuoroquinolones into veterinary medicine
during the late 1980s and early 1990s [11–13],
especially for poultry. A previous regional sur-
veillance study in The Netherlands demonstrated
an increase in ﬂuoroquinolone-resistant campy-
lobacters, from 15% in 1992 to >30% in 2003 [14].
This was an alarming increase, since, among other
reasons, patients infected with ciproﬂoxacin-
resistant Campylobacter strains may have a six-
fold increased risk of invasive illness or death
compared with patients infected with ciproﬂoxa-
cin-susceptible Campylobacter strains [4]. The
present study describes a nationwide epidemio-
logical analysis of culture-proven Campylobacter
infections in The Netherlands during 2000–2004.
PATIENTS AND METHODS
Data from two ongoing projects for surveillance of infectious
diseases in The Netherlands were used.
Laboratory surveillance system (LSI)
Since 1995, 15 regional public health laboratories have report-
ed weekly to the National Institute for Public Health and the
Environment (Bilthoven, The Netherlands) concerning the
total number of ﬁrst isolates of Campylobacter spp., as well as
other bacterial pathogens, and the total number of faecal
samples under investigation. These 15 laboratories are situated
in all regions of The Netherlands and cover c. 50% of the
16 million inhabitants. Since 2002, information concerning the
species and antibiotic resistance against ﬂuoroquinolones,
tetracyclines and erythromycin, and data concerning patient
age, gender, place of residence and recent foreign travel, have
been reported periodically for each ﬁrst isolate.
Infectious disease surveillance information system
In 1994, the National Institute for Public Health and the
Environment developed a computer-based centralised data
system called the ‘infectious diseases surveillance information
system’ (ISIS). ISIS consists of a steadily expanding network of
sentinel laboratories. Early in 2000, seven laboratories partici-
pated, covering 2.6 million inhabitants. During the year 2000,
another three laboratories joined, and since 2001, ten more
laboratories, situated in the middle and south of The Nether-
lands have participated, covering 3.3 million inhabitants.
Participating laboratories transmit electronically all new
results of microbiological investigations to ISIS on a daily
basis. In contrast to most surveillance systems, both positive
and negative laboratory results are recorded. All test results
are anonymously and uniquely coded for each patient. Data
accompanying the laboratory results include information from
the laboratory request form, e.g., age, gender, place of
residence, type of material sampled, type of investigation, test
results, whether the request came from a general practitioner,
specialist or outpatient clinic, and information concerning the
strain and its antibiotic resistance. Information concerning
foreign travel is not available from ISIS. For laboratory test
results, a Campylobacter infection was recorded if a faecal
culture was positive for Campylobacter. In order to include only
one isolate per disease episode, only the ﬁrst positive sample
from each patient during a 6-month period was included in the
analyses.
Analyses
Results are presented for the period 2000–2004. Analysis was
performed at the genus level only, but previous results
indicate that 94% of isolates were Campylobacter jejuni [15–17].
Demographical information, e.g., age and gender, was
obtained from ISIS for individuals with either positive or
negative test results. Age groups were categorised, on the basis
of deﬁnitions used previously [18], as 0–4, 5–14, 15–29, 30–44,
45–59 and ‡60 years. Positive and negative test results were
analysed separately according to age and gender.
Geographical information was most complete for LSI
surveillance, since the laboratories participating in LSI covered
all geographical regions of The Netherlands. For each year,
population size by municipality was obtained from Statistic
Netherlands, and incidences were calculated, with the appro-
priate denominators adjusted for the degree of coverage.
Incidence and resistance rates were analysed according to the
level of urbanisation [14], deﬁned on a scale from 1 (large
cities, >2500 residences ⁄ km2) to 5 (rural municipalities,
<500 residences ⁄km2). Each urbanisation class represented
c. 20% of the Dutch population.
In the ISIS database, seasonal variation in the incidence of
Campylobacter infection was analysed for 2000–2004, and
susceptibility to antibiotics was analysed for 2001–2004. Sus-
ceptibility data have been complete since 2001.
Recent foreign travel was reported only in the LSI project,
and these data were used to study variation in antibiotic
susceptibility among Campylobacter isolates from individuals
with and without a history of recent foreign travel.
Susceptibilities of Campylobacter spp. were determined for
ﬂuoroquinolones (ciproﬂoxacin, oﬂoxacin and ⁄ or norﬂoxacin),
macrolides (erythromycin or clarithromycin) and tetracyclines
(tetracycline or doxycycline).
Statistics
Differences among rates were judged by their relative risk
(RR), using a 95% CI.
RESULTS
Demographics
During the LSI project in 2000–2004, 16 706
campylobacters were reported, whereas 4501 of
the 73 325 samples tested in the ISIS project were
positive for Campylobacter. During 2004, >13 000
faecal samples were tested for Campylobacter in
the laboratories participating in ISIS, of which 885
(6.3%) were positive. Female patients were tested
more frequently for Campylobacter than were
males (1.2:1), but male patients tested for faecal
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pathogens had positive Campylobacter cultures
more often than did females (6.9% vs. 5.4%;
RR 1.27; 95% CI 1.21–1.34).
Patients aged ‡60 years were tested most often,
but were found to be positive in only 2.9% of
cases (Fig. 1). The highest percentage of positive
cultures (11.6%) was observed in the group aged
15–29 years. The highest Campylobacter rates of
resistance against macrolides, ﬂuoroquinolones
and doxycycline ⁄ tetracycline (4.7%, 39% and
21%, respectively) were found in the group aged
45–59 years. RRs of infection with resistant Cam-
pylobacter spp. for the group aged 45–59 years
compared with the group aged 0–4 years were
1.86 (95% CI 0.99–3.47) for macrolides, 1.38
(95% CI 1.18–1.62) for ﬂuoroquinolones, and
1.33 (95% CI 0.95–1.86) for doxycycline ⁄ tetracyc-
line.
Geographical data
The incidence of Campylobacter infections was
highest in the south of The Netherlands, with
49.1 ⁄ 100 000 in the south vs. an average of
37.5 ⁄ 100 000 in other regions of the country
(Table 1). Resistance to macrolides was twice as
high in the south (2.1%) as in the north (1.1%).
The incidence of Campylobacter infection was
lower in rural than in urban or urbanised areas
(32.4 ⁄ 100.000 for scale U5 vs. 41.9 ⁄ 100 000 for
scale U2). Resistance rates increased with increas-
ing urbanisation; this was most apparent for
ﬂuoroquinolones (35.9% for scale U1 vs. 27.1%
for scale U5) (Fig. 2).
Temporal and seasonal trends
In both surveillance systems, the yearly incidence,
as well as the percentage of positive Campylobacter
cultures, was stable during 2000–2004
(41.5 ⁄ 100 000 and 6.1%, respectively), with an
incidental decrease during the year 2003
(33.3 ⁄ 100 000 and 5.3%, respectively). Antibiotic
resistance to the antibiotics investigated was
relatively stable during 2001–2004. Resistance
levels were high for ﬂuoroquinolones (34–36%)
and tetracyclines (18–24%). Evidence of an
increase in resistance was observed for erythro-
mycin (1.9% in 2001 vs. 2.7% in 2004) and
clarithromycin (1.4% in 2001 vs. 4.0% in 2004).
Analysis of ﬂuoroquinolone and macrolide resist-
ance among Campylobacter isolates in the ISIS
project demonstrated an inverse seasonal pattern,
with higher incidence and lower resistance rates
in summer, and lower incidence and higher
resistance rates in winter (Fig. 3). The percentage
of positive Campylobacter cultures was higher in
the winter than in the summer (8.2% vs. 4.3%).
This inverse relationship was conﬁrmed in the LSI
project.
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Fig. 1. Campylobacter isolation rate according to age group,
2000–2004 (source: ISIS).
Table 1. Incidence and resistance rate of Campylobacter
infections according to region during 2002–2004, excluding
travel-related infections (source: LSI)
Region Incidence( ⁄ 100 000)
Fluoroquinolone
resistance (%)
Doxycycline ⁄
tetracycline
resistance (%)
Erythromycin
resistance (%)
North 37.5 30.1 16.0 1.1
Central 34.3 33.7 22.6 1.7
South 49.1 29.8 12.8 2.1
Total 37.3 32.1 18.9 1.6
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Fig. 2. Resistance and incidence (per 100 000 inhabit-
ants ⁄year) related to urbanisation level (excluding travel-
related infections). Level of urbanisation was deﬁned on a
scale from 1 (large cities, >2500 residences ⁄ km2) to 5
(municipalities in the country, <500 residences ⁄ km2). Data
from 2002-2004 are combined (source: LSI).
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Association with foreign travel
Resistance to ﬂuoroquinolones was considerably
higher for travel-related infections (54%) than for
endemic infections (33%) (RR 1.63; 95% CI 1.51–
1.76) (Table 2). The incidence of travel-related
Campylobacter infections was highest in cities with
an urbanisation level of 2–3 (RR 1.54;
95% CI 1.51–1.76; 11.2% of the cases vs. 9.9%),
resulting in a higher overall level of resistance to
ﬂuoroquinolones in this category.
DISCUSSION
This study provided a nationwide epidemiolog-
ical analysis of culture-proven Campylobacter
infection in The Netherlands during 2000–2004.
The elderly (aged ‡60 years) were tested most
frequently, but were found to be positive in only
a minority of cases. This is probably because of
the more frequent occurrence of severe non-
infectious diarrhoea among the elderly, especi-
ally in hospital settings. In contrast, patients in
the group aged 15–29 years were, if tested for
Campylobacter, found to be positive in almost
12% of cases, probably reﬂecting a higher
threshold of symptoms before visiting a general
practitioner in this age category, especially for
males.
In the present analysis, three factors were
found to inﬂuence the incidence and resistance
of campylobacteriosis in The Netherlands, i.e.,
the region, degree of urbanisation and season.
The incidental decrease in the incidence of
Campylobacter for 2003 (33.3 ⁄ 100 000 vs.
41.5 ⁄ 100 000 in other years) might be explained
by a temporary reduction in the sale of (expen-
sive) poultry meat during and after the epidemic
of avian inﬂuenza among poultry in The Nether-
lands during 2003 [17].
Both the incidence and the rates of macrolide
resistance for Campylobacter were highest in the
south of The Netherlands. Although no clear
explanation exists, differences in the preparation
of food, the origin of poultry for consumption
and the frequency of antibiotic treatment may
all play a role. Resistance to erythromycin
appeared to be increasing, particularly in the
south of The Netherlands (>3.2% in some
regions). No macrolide-resistant strains were
detected in C. jejuni isolates from Dutch poultry
(assumed to be an important source of Campy-
lobacter) until 2005 [14]. Human infections with
C. jejuni strains resistant to macrolides are sup-
posedly caused either by consumption of con-
taminated imported products or by host
selection as a result of concomitant antibiotic
treatment for other infections. Indeed, a recent
surveillance study revealed a 20% resistance
rate for erythromycin among Campylobacter iso-
lates in contaminated imported poultry meat (D.
Mevius, personal communication).
The level of urbanisation also had an effect
on the incidence and resistance rates, with
lower incidence rates in rural than in urbanised
areas, and increasing resistance rates with
increasing levels of urbanisation, both including
and excluding travel-related infections (Fig. 2).
An explanation for the higher incidence of
Campylobacter in urbanised areas may be the
presumed higher consumption of ready-to-eat
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Fig. 3. Laboratory-conﬁrmed cases of Campylobacter infec-
tion and resistance rates ⁄month, 2001–2004 (source: ISIS).
Table 2. Antibiotic resistance rates for endemic and
travel-related Campylobacter infections during 2002–2004
(source: LSI)
Antibiotics
Endemic Travel-related
Tests Resistant Tests Resistant
Fluoroquinolones 6520 2179 (33.4%) 645 351 (54.4%)
Doxycycline ⁄ tetracycline 4897 960 (19.6%) 487 132 (27.1%)
Erythromycin 5739 94 (1.6%) 568 12 (2.1%)
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foods. Furthermore, several case-control studies
have found an increased risk associated with
consumption of chicken in restaurants as op-
posed to at home [19–22]. Interestingly, Ethel-
berg et al. [23] associated residence in areas with
a low population density in Denmark with an
increased risk of infection. This increased risk in
rural areas was associated primarily with chil-
dren, and was explained in terms of increased
exposure to farm animals and natural environ-
ments in the countryside as compared with the
city.
Seasonal variation in the incidence of Campylo-
bacter infection and resistance to oﬂoxacin has
been described by Talsma et al. [13] for one
region. A similar inverse relationship was found
in the present study throughout the country, for
both ﬂuoroquinolones and macrolides. Presuma-
bly, different sources of Campylobacter (e.g., swim-
ming water) predominate during summer, and
are associated with lower rates of ﬂuoroquinolone
and macrolide resistance [24]. An alternative
explanation for seasonal variation in resistance
to erythromycin and ﬂuoroquinolones may be
selective pressure resulting from antibiotic ther-
apy for respiratory infections, prescribed most
frequently during the winter.
Resistance to ﬂuoroquinolones has increased
dramatically during the last decade in poultry (an
important source of campylobacters) and humans
(15% in 1992 vs. 35% in 2004) [5,14]. Several
studies have proposed a causal relationship
between veterinary use of ﬂuoroquinolones and
the increase in quinolone-resistant Campylobacter
infections in humans [2,25]. Engberg et al. [5]
identiﬁed three factors associated independently
with an increased risk of a quinolone-resistant
Campylobacter infection in Denmark, i.e., foreign
travel, eating fresh poultry meat other than
chicken and turkey, and swimming [5]. Foreign
travel was also found to be associated with higher
resistance rates in the present study. The relatively
high rate of consumption of antibiotics, including
ﬂuoroquinolones, in southern Europe and large
parts of Asia and the Americas, compared with
north-west Europe, is the most likely explanation
for this observation. In severely-ill patients with
suspected Campylobacter infection, especially in-
fants and elderly patients, the use of antibiotics
may be indicated. The high frequency of ﬂuoro-
quinolone resistance suggests that patients (par-
ticularly those with a history of foreign travel) in
whom severe Campylobacter infection has been
diagnosed should be treated with a macrolide
unless the results of susceptibility testing indicate
otherwise.
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